
Ascelia Pharma - Well placed to secure a partner

Ascelia's Q2 confirmed a contained OPEX base. With support from the recent SPARKLE success and the ongoing secured part of the rights issue, Ascelia is well placed to secure a partner before approval and the launch. Our Base Case is SEK 12 (Bull SEK 31 and Bear SEK 2.3); the main reason for the revision is a high degree of dilution from the rights issue, and our earlier Base Case was SEK 17 (Bull SEK 45 and Bear SEK 6).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Ascelia Pharma - Well placed to secure a partner](#)